Conference

23 June 2022

Save the date & share with us your suggestions for programme items!

More information

Our goal

Working togetherin orderto create thefuture

VR4REHAB aims to stimulate the creation of VR based rehabilitation tools by bringing together relevant stakeholders and exchange knowledge. Working together in order to create the future.

Our goals are:
• Offering a platform to facilitate collaboration
• Linking ideas, people and business
• Providing and exchanging knowledge
• Initiating and showcasing new projects

New publications

A prospective, double-blind, pilot, randomized, controlled trial of an “embodied” virtual reality intervention for adults with low back pain
Eccleston, Christopher; Fisher, Emma; Liikkanen, Sammeli; Sarapohja, Toni; Stenfors, Carina; Jääskeläinen, Satu K.; Rice, Andrew S.C.; Mattila, Leenad; Blom, Taru; Bratty, J. Raymond

"Adults with chronic low back pain, disability, moderate-to-severe pain, and high fear of movement and reinjury were recruited into a trial of a novel, automated, digital therapeutics, virtual reality, psychological intervention for pain (DTxP). We conducted a 3-arm, prospective, double-blind, pilot, randomized, controlled trial comparing DTxP with a sham placebo comparator and an open-label standard care."

DOI: 10.1097/j.pain.0000000000002617
Read full article
A prospective, double-blind, pilot, randomized, controlled trial of an “embodied” virtual reality intervention for adults with low back pain
Eccleston, Christopher; Fisher, Emma; Liikkanen, Sammeli; Sarapohja, Toni; Stenfors, Carina; Jääskeläinen, Satu K.; Rice, Andrew S.C.; Mattila, Leenad; Blom, Taru; Bratty, J. Raymond
DOI: 10.1097/j.pain.0000000000002617

"Adults with chronic low back pain, disability, moderate-to-severe pain, and high fear of movement and reinjury were recruited into a trial of a novel, automated, digital therapeutics, virtual reality, psychological intervention for pain (DTxP). We conducted a 3-arm, prospective, double-blind, pilot, randomized, controlled trial comparing DTxP with a sham placebo comparator and an open-label standard care."

Read full article